Aside from the dilution, I believe David has done a commendable job turning around the company into a potential powerhouse in the battery space, The credit raisings were a bit questionable, but we don’t have full insight into the details or whether anyone was willing to contribute capital unless the terms were highly favorable to the investors.
Life Sciences has shown a turnaround under his leadership. Previously, we were constantly dealing with collaborators who seemed to be stuck in an endless cycle of testing. A big shoutout to David and his team for that progress.
As for ANTeo X, we’re working with major companies who won’t commit until the testing is absolutely flawless. Hopefully, Fabian can help streamline the process. My only thought is whether we should have pursued some easier opportunities for quicker wins along the way.
So, are we going to hold him accountable for the credit raisings, which, while costly, are necessary to keep the company running until we secure deals and boost the share price? It is what it is the company has a heavy cost every QTR with wages until the $$$ coming in is greater than $$$ going out then you do the maths it's not rocket science—if we had another CEO, would the outcome have been any better, or even worse? Just something to consider - Be careful what you wish for.
Cheers
M.oz
ADO Price at posting:
1.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)